Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+ regulatory T cells. These cells might suppress tumor-specific immune responses. Cyclophosphamide has been shown to reduce the frequency of CD4+CD25+ regulatory T cells. The aim of this study is to test if the treatment with cyclophosphamide leads to a decrease in the frequency of CD4+CD25+ regulatory T cells and to increase tumor specific immune responses in patients with advanced HCC.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hannover Medical School
• Treatments: Cyclophosphamide

Criteria

Inclusion Criteria:

• adequate WBC

• adequate liver and kidney function

• no immunodeficiency

• ECOG < 2

Exclusion Criteria:

• advanced liver cirrhosis

• severe cardiopulmonary diseases